Nicholas Johnson is a Neurology physician. ClinicalTrials.gov lists 11 registered studies matched to this name.
Overview
Scholarship
indexed output and impact (OpenAlex)Research metrics aren't shown for this record. Either we found no confident publication match for this name, or more than one physician shares the matched author record. We'd rather show nothing than someone else's numbers. Why? →
Clinical & industry
trials, payments and federal fundingContact
The practice address and phone this provider lists in the federal NPPES (CMS) registry.
Practice address
175 N Medical Dr E
Salt Lake City, UT 841325901
Telephone
801-585-7575Registry record last updated 27 Nov 2013.
Clinical trials
- Establishing Biomarkers and Clinical Endpoints in Myotonic Dystrophy Type 1 (END-DM1) Extension
Sponsor: Virginia Commonwealth University
- Trial Readiness and Endpoint Assessment in Pediatric Myotonic Dystrophy Extension
Sponsor: Virginia Commonwealth University
- Long-Term Development of Muscular Dystrophy Outcome Assessments
Sponsor: Virginia Commonwealth University
Registered studies on ClinicalTrials.gov where the overall official or a site investigator name-matches this physician, confirmed against known institution/geography. Latest few shown; the full list is part of the full profile.
Industry payments
12 companies reported payments to CMS in program years 2021 onward. These are public disclosures, not judgments. The latest:
- Sarepta Therapeutics, Inc.Program year202510 payments
- ARGENX US, INC.Program year20253 payments
- Novartis Pharmaceuticals CorporationProgram year20255 payments
Payment records matched to this physician's NPI in CMS Open Payments, program years 2021 onward.
Medicare prescribing footprint (2024)
The drugs this prescriber writes for Medicare patients, grouped by drug class and therapeutic area. Every percentage is a share of their total prescribing, so you can see what they prescribe most. These are proportions, not patient counts or dollar amounts. No condition is inferred: the claims record what was prescribed, never why.
Nervous system
69.9%Gabapentinoids32.1%Pregabalin52%Gabapentin48%Part D<11 patientsOther nervous system drugs21.8%Skyclarys100%Part D<11 patients+ 2 more classes in this area
Musculoskeletal
21.2%Survival of Motor Neuron 2 Splicing Modifier12.8%Evrysdi100%Part D<11 patientsgamma-Aminobutyric Acid-ergic Agonist8.3%Baclofen100%Part D<11 patientsCardiovascular
9%Antiarrhythmic9%Mexiletine Hcl100%Part D<11 patients
Drug classes come from the WHO ATC and U.S. National Library of Medicine (RxClass) classifications; prescribing counts come from the CMS Medicare Part D Prescribers file. Each drug is counted once, under its primary class. Medicare fee-for-service only, so no Medicare Advantage, commercial, or pediatric prescribing is included. CMS publishes this data about 17 months after the fact.
NIH funding
3 NIH research awards on record, funded 2015–2018 per NIH RePORTER. The latest:
- Health Endpoints and Longitudinal Progression in Congenital Myotonic Dystrophy (HELP-CDM)
University of Utah
FY2018$51,102K23NS091511 - Health Endpoints and Longitudinal Progression in Congenital Myotonic Dystrophy (HELP-CDM)
University of Utah
FY2017$201,960K23NS091511
Awards in the NIH RePORTER records where a principal investigator name matches this physician at an organization in their practice state. Latest award years shown; each row links to the project record on RePORTER.
Similar KOLs
Other experts from the same institution or the same specialty.
Atte Meretoja
University of Helsinki
Bruce Miller, MD
University of California, San Francisco (UCSF)
Dennis Selkoe, MD
Brigham and Women's Hospital
Ettore Beghi
Mario Negri Institute for Pharmacological Research
A basic profile from our physician directory: identity and practice contact from the federal NPPES registry, research from OpenAlex, trials from ClinicalTrials.gov, payments from CMS Open Payments — shown itemized where we have matched records, as a count where we only have a total. This person hasn't been through our full identity-adjudication pipeline yet, so funding, congress activity and public presence aren't shown. Absence of a section means “not yet looked,” never “none found.”